Sir,

The use of therapeutic agent for the cancerous patient with underlying disease must be carefully done. An important common hematological disorder that can be seen around the world is G-6-PD deficiency. The problem of the effectiveness of the cancer therapy regimen and the possible trigger on deficient red blood cell are the important concerns.\[[@ref1]\] Here, the author reports an experience on a case with post-colectomy colon cancer. This case is a referred case consulting on the problem of prolonged anemia. The patient has been diagnosed for colon cancer and got surgical treatment with capecitabine chemotherapy for 1 year. The patient has also got the additional new immunotherapy by nimotuzumab regimen. On the consulting visit, this patient was completely investigated for possible cause of hematological disorder and the G-6-PD deficiency was detected. Focusing on blood picture, normochromic normocytic anemia without evidence of hemolysis could be seen. Based on this history, it can be seen that using new nimotuzumab treatment in cancerous patient did not lead to hemolytic blood picture. This is the first world report that nimotuzumab should be safe for the patient with G-6-PD deficiency. The left issue is to follow-up and study the efficacy of nimotuzumab in the case with G-6-PD deficiency.
